Evidence map›Paper›PMID 34527198›Full record

ArticleComputational and structural biotechnology journal2021

MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer.

Bing-Biao Lin, Han-Qi Lei, Hai-Yun Xiong, Xing Fu, Fu Shi, Xiang-Wei Yang, Ya-Fei Yang, Guo-Long Liao, Yu-Peng Feng, Dong-Gen Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. PET imaging of new target CDK19 in prostate cancer.European journal of nuclear medicine and molecular imaging · 2023
    Article
  13. Article
  14. Article
  15. MicroRNA Dysregulation in Prostate Cancer.Pharmacogenomics and personalized medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bing-Biao LinDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Han-Qi LeiDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Hai-Yun XiongDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Xing FuSchool of Medicine, Southern University of Science and Technology, 1088 Xueyuan Road, Shenzhen, Guangdong 518055, China.
Fu ShiDepartment of Reproductive Medicine Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong 518000, China.
Xiang-Wei YangDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Ya-Fei YangDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Guo-Long LiaoDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Yu-Peng FengDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Dong-Gen JiangDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.
Jun PangDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miRNA) deregulation plays a critical role in the heterogeneous development of prostate cancer (PCa) by tuning mRNA levels. Herein, we aimed to characterize the molecular features of PCa by clustering the miRNA-regulated transcriptome with non-negative matrix factorization. Using 478 PCa samples from The Cancer Genome Atlas, four molecular subtypes (S-I, S-II, S-III, and S-IV) were identified and validated in two merged microarray and RNAseq datasets with 656 and 252 samples, respectively. Interestingly, the four subtypes showed distinct clinical and biological features after comprehensive analyses of clinical features, multiomic profiles, immune infiltration, and drug sensitivity. S-I is basal/stem/mesenchymal-like and immune-excluded with marked transforming growth factor

Indexed as

ADT, androgen deprivation therapyAR, androgen receptorAUC, Area under the dose-response curveBCR, biochemical recurrenceCAFs, cancer-associated fibroblastsCCLs, cancer cell linesCTLA-4, cytotoxic T-lymphocyte associated protein-4DEmiRs, differentially expressed miRNAsDFS, disease-free survivalEMT, epithelial-mesenchymal transitionFDR, false discovery rateGEO, Gene Expression OmnibusGEP, gene expression profileGO, Gene OntologyGSEA, Gene Set Enrichment AnalysisHeterogeneityICB, immune checkpoint blockadeIFN, interferonKEGG, Kyoto Encyclopedia of Genes and Genomesk-NN, K-nearest neighbormCRPC, metastatic castration-resistant prostate cancerMDSCs, myeloid-derived suppressor cellsMIRcor, miRNA-correlatedmiRNAsmiRNAs, microRNAsMolecular subtypesNEPC, neuroendocrine prostate cancerNMF, non-negative matrix factorizationNTP, Nearest template predictionOS, overall survivalPCa, prostate cancerPD-1, programmed cell death protein-1PD-L1, programmed death-ligand 1Prostate cancerSCNAs, somatic copy number alterationsssGSEA, single-sample gene set enrichment analysisSubMap, Subclass mappingTCGA, The Cancer Genome AtlasTGFβ, transforming growth factor βTMB, tumor mutation burdenTNAs, tumor neoantigensTregs, regulatory T cells

Identifiers

PMID34527198
PMCPMC8433071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.